(Press-News.org) About The Study: In a large sample of U.S. children born between 1959 and 1966, higher blood pressure (BP) at age 7 was associated with greater risk of premature cardiovascular disease (CVD) mortality. These findings build upon prior research that linked childhood systolic BP with fatal CVD in young adulthood, but that sample had a follow-up duration through a mean age of only 46 years. This study extends that work with follow-up into the mid-50s and demonstrated consistency in the magnitude of the associations within siblings, which mitigates concerns regarding unmeasured confounding due to shared family or lifestyle characteristics.
Corresponding Author: To contact the corresponding author, Alexa A. Freedman, PhD, email alexa.freedman@northwestern.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.14405)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the AHA Hypertension Scientific Sessions 2025.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14405?guestAccessKey=9084f39a-f4d2-4b96-82f5-8f38e70c60f0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090725
END
High blood pressure in childhood and premature cardiovascular disease mortality
JAMA
2025-09-07
ELSE PRESS RELEASES FROM THIS DATE:
Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations
2025-09-07
(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who had progressed on prior TKI therapy.
ROS1-positive NSCLC occurs in approximately 1–2% of all NSCLC cases.
The results from the Phase ...
Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC
2025-09-07
(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase 3 E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
The trial, conducted within the ALCHEMIST clinical trials program, ...
Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy
2025-09-07
Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy
(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) — Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).
Results from the global Phase 3 HARMONi trial were presented today by Jonathan ...
FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC
2025-09-07
(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).
These findings, presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer, support osimertinib plus chemotherapy as a new standard-of-care ...
Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study
2025-09-07
Contact: Chris Martin, MPH IASLC Media Relations cmartin@davidjamesgroup.com
(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) – New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations.
The results were presented by Dr. Jie Wang, National Cancer Center, ...
New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients
2025-09-06
Contact: Chris Martin, MPH/IASLC Media Relations/cmartin@davidjamesgroup.com
(Barcelona, Spain — September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
Iza-bren is a first-in-class EGFR x HER3 bispecific ADC linked to a novel topoisomerase I inhibitor payload (Ed-04). The drug was evaluated ...
Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds
2025-09-06
Iza-Bren in combination with Osimertinib Shows 100% Response Rate in EGFR-Mutated NSCLC, Phase II Study Finds
Barcelona, Spain (September, 2025) —A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
This study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
Iza-bren is a first-in-class ADC combining EGFR and HER3 targeting with a topoisomerase I inhibitor payload. The study tested iza-bren at multiple ...
COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC
2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy.
The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The COMPEL study is a global, randomized, double-blind trial, in which adult patients with non-CNS progression on first-line osimertinib were randomized 1:1 to receive either osimertinib ...
CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC
2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease.
These results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The study assessed HRQoL by nodal status and surgical outcomes using patient-reported outcome (PRO) measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual ...
Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital
2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population.
The study, conducted by the University of Illinois Hospital & Clinics, (UI Health), the academic health enterprise of the University of Illinois Chicago (UIC), highlights Sybil’s strong performance in a real-world clinical setting with racially and socioeconomically ...
LAST 30 PRESS RELEASES:
Could hidden infections be fueling long COVID?
Targeted oxygen for initial resuscitation of preterm infants
Researchers develop models to help diagnose ALS earlier through blood biomarkers
Jeonbuk National University researchers develop novel eco-friendly and photo-switchable smart adhesives
Magnetic ordering induces Jahn–Teller effect in spinel-type compounds
A mitochondrial protein may hold the secret to longevity, new study finds
Study shows how everyday repairs sustain autonomy in a Japanese squat
Ancient manatee relative reveals that sea cows have engineered the Arabian Gulf’s seagrass ecosystems for over 20 million years
Fecal tests reveal active termite attacks
Uterine fibroids linked to elevated heart disease risk
Dual use of cigarettes and vapes can reduce risks of smoking and help smokers quit
New bioelectronics device based on hydrogel- elastomer conductive nanomembranes
More yield through heterosis: IPK research team decodes gene interaction
James Webb telescope reveals spectacular atmospheric escape
ICE-CSIC leads a pioneering study on the feasibility of asteroid mining
Dramatic rise in young people using mental health services
Be careful trusting TikTok for gout advice
A study by the University of Seville links the vanishing of the specific heats at absolute zero with the principle of entropy increase
Anxiety and insomnia may lower natural killer cell count, potentially repressing immune function
How parasitic, asexual plants evolve and live
Research spotlight: A subset of patients with depression could benefit from anti-inflammatory treatment
New fully digital design paves the way for scalable probabilistic computing
Membrane electrode assembly design for high-efficiency anion exchange membrane water electrolysis
U.S. debt ceiling disputes show measurable impact on global crude oil markets
Climate extremes triggered rare coral disease and mass mortality on the Great Barrier Reef
Direct observation reveals “two-in-one” roles of plasma turbulence
Humans rank between meerkats and beavers in monogamy ‘league table’
US fossil reveals early mass-burial event and ancient microbial attack
Sedative choice could improve outcomes for breathing tube patients
New superconducting thin film for quantum computer chips
[Press-News.org] High blood pressure in childhood and premature cardiovascular disease mortalityJAMA